Literature DB >> 26184015

Clinical features and management of type I gastric carcinoids.

Yuichi Sato1.   

Abstract

Type I gastric carcinoids (TIGCs) are related to chronic atrophic gastritis and are characterized by hypergastrinemia and hyperplasia of enterochromaffin-like cells. TIGCs are the most frequently diagnosed of all gastric carcinoids, accounting for about 70-80 %. Endoscopically, TIGCs are present as small (<10 mm), polypoid lesions or, more frequently, as smooth, rounded submucosal lesions. Histologically, TIGCs arise in the deep mucosa, with some invading the submucosa. Most TIGCs are well-differentiated tumors, with metastasis being rare. Therefore, patients with TIGCs generally have an excellent prognosis. Among the currently available treatment options are total gastrectomy, partial resection, antrectomy, endoscopic resection, and endoscopic surveillance, although no consensus has been reached on their optimal management. Further studies are needed to develop better management options for patients with TIGC.

Entities:  

Mesh:

Year:  2014        PMID: 26184015     DOI: 10.1007/s12328-014-0528-9

Source DB:  PubMed          Journal:  Clin J Gastroenterol        ISSN: 1865-7265


  55 in total

Review 1.  Standard imaging techniques for neuroendocrine tumors.

Authors:  David L Bushnell; Richard P Baum
Journal:  Endocrinol Metab Clin North Am       Date:  2011-03       Impact factor: 4.741

Review 2.  Histopathological classification of nonantral gastric endocrine growths in man.

Authors:  E Solcia; C Bordi; W Creutzfeldt; Y Dayal; A D Dayan; S Falkmer; L Grimelius; N Havu
Journal:  Digestion       Date:  1988       Impact factor: 3.216

3.  Antigastric autoantibodies in Helicobacter pylori infection: implications of histological and clinical parameters of gastritis.

Authors:  G Faller; H Steininger; J Kränzlein; H Maul; T Kerkau; J Hensen; E G Hahn; T Kirchner
Journal:  Gut       Date:  1997-11       Impact factor: 23.059

4.  Ability of somatostatin receptor scintigraphy to identify patients with gastric carcinoids: a prospective study.

Authors:  F Gibril; J C Reynolds; I A Lubensky; P K Roy; P L Peghini; J L Doppman; R T Jensen
Journal:  J Nucl Med       Date:  2000-10       Impact factor: 10.057

Review 5.  Gastric carcinoid tumors: the biology and therapy of an enigmatic and controversial lesion.

Authors:  C J Gilligan; G P Lawton; L H Tang; A B West; I M Modlin
Journal:  Am J Gastroenterol       Date:  1995-03       Impact factor: 10.864

Review 6.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

Authors:  James C Yao; Manal Hassan; Alexandria Phan; Cecile Dagohoy; Colleen Leary; Jeannette E Mares; Eddie K Abdalla; Jason B Fleming; Jean-Nicolas Vauthey; Asif Rashid; Douglas B Evans
Journal:  J Clin Oncol       Date:  2008-06-20       Impact factor: 44.544

7.  Treatment of gastric carcinoids type 1 with the gastrin receptor antagonist netazepide (YF476) results in regression of tumours and normalisation of serum chromogranin A.

Authors:  R Fossmark; Ø Sørdal; C S Jianu; G Qvigstad; I S Nordrum; M Boyce; H L Waldum
Journal:  Aliment Pharmacol Ther       Date:  2012-10-16       Impact factor: 8.171

8.  Gastric endocrine tumors type I: treatment with long-acting somatostatin analogs.

Authors:  D Campana; F Nori; R Pezzilli; L Piscitelli; D Santini; E Brocchi; R Corinaldesi; P Tomassetti
Journal:  Endocr Relat Cancer       Date:  2008-03       Impact factor: 5.678

9.  Long-term follow-up of a large series of patients with type 1 gastric carcinoid tumors: data from a multicenter study.

Authors:  Dimitrios Thomas; Apostolos V Tsolakis; Simona Grozinsky-Glasberg; Merav Fraenkel; Krystallenia Alexandraki; Stavros Sougioultzis; David J Gross; Gregory Kaltsas
Journal:  Eur J Endocrinol       Date:  2013-01-17       Impact factor: 6.664

10.  Current concepts on gastric carcinoid tumors.

Authors:  George C Nikou; Theodoros P Angelopoulos
Journal:  Gastroenterol Res Pract       Date:  2012-12-17       Impact factor: 2.260

View more
  5 in total

1.  Comparison of characteristics between true rectal neuroendocrine tumors and rectal hyperplastic polyps among patients with endoscope-diagnosed rectal neuroendocrine tumors.

Authors:  Yan Weng; Jingxue Ran; Yongmei Peng; Yining Xiang; Liangbi Xu
Journal:  J Gastrointest Oncol       Date:  2022-06

2.  Pedunculated gastric neuroendocrine tumor: a case report.

Authors:  Kenichi Takeda; Shin-Ei Kudo; Fumio Ishida
Journal:  Endosc Int Open       Date:  2016-09-30

3.  Clinical features and outcomes of gastric neuroendocrine tumors after endoscopic diagnosis and treatment: A Digestive Endoscopy Society of Tawian (DEST).

Authors:  Chen-Shuan Chung; Cho-Lun Tsai; Yin-Yi Chu; Kuan-Chih Chen; Jung-Chun Lin; Bao-Chung Chen; Wei-Chih Sun; Hsu-Heng Yen; Chiung-Yu Chen; I-Chen Wu; Chao-Hung Kuo; Hisang-Yao Shih; Ming-Jong Bair; Jack P Wang; Wen-Hao Hu; Chang-Shyue Yang; Ming-Lun Han; Tsu-Yao Cheng; Chao-Ming Tseng; Ming-Chang Tsai; Ming-Luen Hu; Hsiu-Po Wang
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.817

4.  Endoscopic surveillance alone is feasible and safe in type I gastric neuroendocrine neoplasms less than 10 mm in diameter.

Authors:  Klaire Exarchou; Haiyi Hu; Nathan A Stephens; Andrew R Moore; Mark Kelly; Angela Lamarca; Wasat Mansoor; Richard Hubner; Mairéad G McNamara; Howard Smart; Nathan R Howes; Juan W Valle; D Mark Pritchard
Journal:  Endocrine       Date:  2022-07-27       Impact factor: 3.925

5.  Gastric carcinoid tumor after laparoscopic gastric banding: Case report of a patient with weight regain.

Authors:  Daniel N Velasco Hernández; Santiago B De Battista; Héctor R Horiuchi; Maria M Zicavo
Journal:  Int J Surg Case Rep       Date:  2018-09-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.